Treatment of juvenile rheumatoid arthritis

The systematic approach to pharmacologic treatment is typically to begin with the safest, simplest, and most conservative measures. It has been realized that the more rapidly inflammation is under control, the less likely it is that there will be permanent sequelae. Nonsteroidal anti-inflammatory dr...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental pediatrics 2010, 53(11), , pp.936-941
Main Author: Kim, Kwang Nam
Format: Article
Language:English
Subjects:
Anti-inflammatory agents
Arthritis
Aspirin
Child
Children & youth
Disease modifying antirheumatic drugs
Drug dosages
Drug withdrawal
Food
Inflammation
Juvenile arthritis
Non-steroidal anti-inflammatory agents
Nonsteroidal anti-inflammatory drugs
Oral administration
Remission (Medicine)
Review
Steroids
Systemic diseases
Therapy
Toxicity
소아과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4436-3d4063b933ef05500c0aebb6e6169e5cacee2980181af13b8fd89431f8df1d813
cites cdi_FETCH-LOGICAL-c4436-3d4063b933ef05500c0aebb6e6169e5cacee2980181af13b8fd89431f8df1d813
container_end_page 941
container_issue 11
container_start_page 936
container_title Clinical and experimental pediatrics
container_volume 53
creator Kim, Kwang Nam
description The systematic approach to pharmacologic treatment is typically to begin with the safest, simplest, and most conservative measures. It has been realized that the more rapidly inflammation is under control, the less likely it is that there will be permanent sequelae. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the mainstay of initial treatment for inflammation. In addition, the slow-acting antirheumatic drugs (SAARDs) and disease-modifying antirheumatic drugs (DMARDs) have efficacy of anti-inflammatory action in children with chronic arthritis. New therapeutic modalities for inflammation, such as etanercept and infliximab, promise even further improvements in the risk/benefit ratio of treatment. It is not typically possible at the onset of the disease to predict which children will recover and which will go on to have unremitting disease with lingering disability or enter adulthood with serious functional impairment. Therefore, the initial therapeutic approach must be vigorous in all children.
doi_str_mv 10.3345/kjp.2010.53.11.936
format article
fullrecord <record><control><sourceid>proquest_nrf_k</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_298382</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_bc4f581a50744ce69ba6a96ad12afdf7</doaj_id><sourcerecordid>2595041145</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4436-3d4063b933ef05500c0aebb6e6169e5cacee2980181af13b8fd89431f8df1d813</originalsourceid><addsrcrecordid>eNpdklFrFDEQx4Mo9qx-AR_kwAdF2DOTSbLZF6EUtQeFQjmfQzab9LK3uzmzuwW_vbm7WlqfhmT-85vJ5E_Ie6ArRC6-7tr9itF8ErgCWFUoX5AFoxUrSibUS7KAElUBVMIZeTOOLaWSc8lekzMGDBQFsSBfNsmZqXfDtIx-2c73bgidW6atm3szxdAsTZq2KUxhfEteedON7t1DPCe_fnzfXF4V1zc_15cX14XlHGWBDacS6wrReSoEpZYaV9fSSZCVE9ZY51iVuyswHrBWvlEVR_Cq8dAowHPy-cQdktc7G3Q04Rjvot4lfXG7WesMQMWydH2SNtG0ep9Cb9Kfo_54EdOdzuMH2zldW-5Fbiloybl1sqqNNJU0DTDjG19m1rcTaz_XvWtsXkky3TPo88wQtnmke40UGCsxAz49AFL8Pbtx0n0Yres6M7g4j1qhgLx1eWj18T9lG-c05KVqJipBOQAXWcVOKpviOCbnH2cBqg8G0NkA-mAALVAD6GyAXPTh6SseS_79OP4F16Grcg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2595041145</pqid></control><display><type>article</type><title>Treatment of juvenile rheumatoid arthritis</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Kim, Kwang Nam</creator><creatorcontrib>Kim, Kwang Nam</creatorcontrib><description>The systematic approach to pharmacologic treatment is typically to begin with the safest, simplest, and most conservative measures. It has been realized that the more rapidly inflammation is under control, the less likely it is that there will be permanent sequelae. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the mainstay of initial treatment for inflammation. In addition, the slow-acting antirheumatic drugs (SAARDs) and disease-modifying antirheumatic drugs (DMARDs) have efficacy of anti-inflammatory action in children with chronic arthritis. New therapeutic modalities for inflammation, such as etanercept and infliximab, promise even further improvements in the risk/benefit ratio of treatment. It is not typically possible at the onset of the disease to predict which children will recover and which will go on to have unremitting disease with lingering disability or enter adulthood with serious functional impairment. Therefore, the initial therapeutic approach must be vigorous in all children.</description><identifier>ISSN: 1738-1061</identifier><identifier>EISSN: 2092-7258</identifier><identifier>EISSN: 2713-4148</identifier><identifier>DOI: 10.3345/kjp.2010.53.11.936</identifier><identifier>PMID: 21218015</identifier><language>eng</language><publisher>Korea (South): Clinical and Experimental Pediatics / Korean Pediatric Society</publisher><subject>Anti-inflammatory agents ; Arthritis ; Aspirin ; Child ; Children &amp; youth ; Disease modifying antirheumatic drugs ; Drug dosages ; Drug withdrawal ; Food ; Inflammation ; Juvenile arthritis ; Non-steroidal anti-inflammatory agents ; Nonsteroidal anti-inflammatory drugs ; Oral administration ; Remission (Medicine) ; Review ; Steroids ; Systemic diseases ; Therapy ; Toxicity ; 소아과학</subject><ispartof>Clinical and Experimental Pediatrics, 2010, 53(11), , pp.936-941</ispartof><rights>2010. This work is published under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2010 by The Korean Pediatric Society 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4436-3d4063b933ef05500c0aebb6e6169e5cacee2980181af13b8fd89431f8df1d813</citedby><cites>FETCH-LOGICAL-c4436-3d4063b933ef05500c0aebb6e6169e5cacee2980181af13b8fd89431f8df1d813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2595041145/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2595041145?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,313,314,727,780,784,792,885,25753,27922,27924,27925,37012,44590,53791,53793,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21218015$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001500036$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Kwang Nam</creatorcontrib><title>Treatment of juvenile rheumatoid arthritis</title><title>Clinical and experimental pediatrics</title><addtitle>Korean J Pediatr</addtitle><description>The systematic approach to pharmacologic treatment is typically to begin with the safest, simplest, and most conservative measures. It has been realized that the more rapidly inflammation is under control, the less likely it is that there will be permanent sequelae. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the mainstay of initial treatment for inflammation. In addition, the slow-acting antirheumatic drugs (SAARDs) and disease-modifying antirheumatic drugs (DMARDs) have efficacy of anti-inflammatory action in children with chronic arthritis. New therapeutic modalities for inflammation, such as etanercept and infliximab, promise even further improvements in the risk/benefit ratio of treatment. It is not typically possible at the onset of the disease to predict which children will recover and which will go on to have unremitting disease with lingering disability or enter adulthood with serious functional impairment. Therefore, the initial therapeutic approach must be vigorous in all children.</description><subject>Anti-inflammatory agents</subject><subject>Arthritis</subject><subject>Aspirin</subject><subject>Child</subject><subject>Children &amp; youth</subject><subject>Disease modifying antirheumatic drugs</subject><subject>Drug dosages</subject><subject>Drug withdrawal</subject><subject>Food</subject><subject>Inflammation</subject><subject>Juvenile arthritis</subject><subject>Non-steroidal anti-inflammatory agents</subject><subject>Nonsteroidal anti-inflammatory drugs</subject><subject>Oral administration</subject><subject>Remission (Medicine)</subject><subject>Review</subject><subject>Steroids</subject><subject>Systemic diseases</subject><subject>Therapy</subject><subject>Toxicity</subject><subject>소아과학</subject><issn>1738-1061</issn><issn>2092-7258</issn><issn>2713-4148</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdklFrFDEQx4Mo9qx-AR_kwAdF2DOTSbLZF6EUtQeFQjmfQzab9LK3uzmzuwW_vbm7WlqfhmT-85vJ5E_Ie6ArRC6-7tr9itF8ErgCWFUoX5AFoxUrSibUS7KAElUBVMIZeTOOLaWSc8lekzMGDBQFsSBfNsmZqXfDtIx-2c73bgidW6atm3szxdAsTZq2KUxhfEteedON7t1DPCe_fnzfXF4V1zc_15cX14XlHGWBDacS6wrReSoEpZYaV9fSSZCVE9ZY51iVuyswHrBWvlEVR_Cq8dAowHPy-cQdktc7G3Q04Rjvot4lfXG7WesMQMWydH2SNtG0ep9Cb9Kfo_54EdOdzuMH2zldW-5Fbiloybl1sqqNNJU0DTDjG19m1rcTaz_XvWtsXkky3TPo88wQtnmke40UGCsxAz49AFL8Pbtx0n0Yres6M7g4j1qhgLx1eWj18T9lG-c05KVqJipBOQAXWcVOKpviOCbnH2cBqg8G0NkA-mAALVAD6GyAXPTh6SseS_79OP4F16Grcg</recordid><startdate>20101101</startdate><enddate>20101101</enddate><creator>Kim, Kwang Nam</creator><general>Clinical and Experimental Pediatics / Korean Pediatric Society</general><general>The Korean Pediatric Society</general><general>Korean Pediatric Society</general><general>대한소아청소년과학회</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><scope>ACYCR</scope></search><sort><creationdate>20101101</creationdate><title>Treatment of juvenile rheumatoid arthritis</title><author>Kim, Kwang Nam</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4436-3d4063b933ef05500c0aebb6e6169e5cacee2980181af13b8fd89431f8df1d813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Anti-inflammatory agents</topic><topic>Arthritis</topic><topic>Aspirin</topic><topic>Child</topic><topic>Children &amp; youth</topic><topic>Disease modifying antirheumatic drugs</topic><topic>Drug dosages</topic><topic>Drug withdrawal</topic><topic>Food</topic><topic>Inflammation</topic><topic>Juvenile arthritis</topic><topic>Non-steroidal anti-inflammatory agents</topic><topic>Nonsteroidal anti-inflammatory drugs</topic><topic>Oral administration</topic><topic>Remission (Medicine)</topic><topic>Review</topic><topic>Steroids</topic><topic>Systemic diseases</topic><topic>Therapy</topic><topic>Toxicity</topic><topic>소아과학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Kwang Nam</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><collection>Korean Citation Index</collection><jtitle>Clinical and experimental pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Kwang Nam</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of juvenile rheumatoid arthritis</atitle><jtitle>Clinical and experimental pediatrics</jtitle><addtitle>Korean J Pediatr</addtitle><date>2010-11-01</date><risdate>2010</risdate><volume>53</volume><issue>11</issue><spage>936</spage><epage>941</epage><pages>936-941</pages><issn>1738-1061</issn><eissn>2092-7258</eissn><eissn>2713-4148</eissn><abstract>The systematic approach to pharmacologic treatment is typically to begin with the safest, simplest, and most conservative measures. It has been realized that the more rapidly inflammation is under control, the less likely it is that there will be permanent sequelae. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the mainstay of initial treatment for inflammation. In addition, the slow-acting antirheumatic drugs (SAARDs) and disease-modifying antirheumatic drugs (DMARDs) have efficacy of anti-inflammatory action in children with chronic arthritis. New therapeutic modalities for inflammation, such as etanercept and infliximab, promise even further improvements in the risk/benefit ratio of treatment. It is not typically possible at the onset of the disease to predict which children will recover and which will go on to have unremitting disease with lingering disability or enter adulthood with serious functional impairment. Therefore, the initial therapeutic approach must be vigorous in all children.</abstract><cop>Korea (South)</cop><pub>Clinical and Experimental Pediatics / Korean Pediatric Society</pub><pmid>21218015</pmid><doi>10.3345/kjp.2010.53.11.936</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1738-1061
ispartof Clinical and Experimental Pediatrics, 2010, 53(11), , pp.936-941
issn 1738-1061
2092-7258
2713-4148
language eng
recordid cdi_nrf_kci_oai_kci_go_kr_ARTI_298382
source Publicly Available Content Database; PubMed Central
subjects Anti-inflammatory agents
Arthritis
Aspirin
Child
Children & youth
Disease modifying antirheumatic drugs
Drug dosages
Drug withdrawal
Food
Inflammation
Juvenile arthritis
Non-steroidal anti-inflammatory agents
Nonsteroidal anti-inflammatory drugs
Oral administration
Remission (Medicine)
Review
Steroids
Systemic diseases
Therapy
Toxicity
소아과학
title Treatment of juvenile rheumatoid arthritis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T02%3A29%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_nrf_k&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20juvenile%20rheumatoid%20arthritis&rft.jtitle=Clinical%20and%20experimental%20pediatrics&rft.au=Kim,%20Kwang%20Nam&rft.date=2010-11-01&rft.volume=53&rft.issue=11&rft.spage=936&rft.epage=941&rft.pages=936-941&rft.issn=1738-1061&rft.eissn=2092-7258&rft_id=info:doi/10.3345/kjp.2010.53.11.936&rft_dat=%3Cproquest_nrf_k%3E2595041145%3C/proquest_nrf_k%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4436-3d4063b933ef05500c0aebb6e6169e5cacee2980181af13b8fd89431f8df1d813%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2595041145&rft_id=info:pmid/21218015&rfr_iscdi=true